21 results on '"Simone, Nicole L."'
Search Results
2. A systematic review of home-based dietary interventions during radiation therapy for cancer
- Author
-
Allenby, Taylor H., Crenshaw, Megan L., Mathis, Katlynn, Champ, Colin E., Simone, Nicole L., Schmitz, Kathryn H., Tchelebi, Leila T., and Zaorsky, Nicholas G.
- Published
- 2020
- Full Text
- View/download PDF
3. Baseline single institutional retrospective review of body mass index (BMI) as a prognostic indicator in patients with newly diagnosed glioblastoma (GBM).
- Author
-
Cappelli, Louis, Uppendahl, Adam, Gardner, Christopher, Khan, Mehak, Kayne, Allison, Vemula, Sudheshna, Poiset, Spencer J., Zhan, Tinging, Judy, Kevin D., Andrews, David W., Simone, Nicole L., Alnahhas, Iyad, and Shi, Wenyin
- Abstract
• Normal BMI linked to longer survival in GBM patients, challenging the obesity paradox. • MGMT methylation status identified as a potentially stronger survival indicator than BMI in GBM. • Analysis reveals high BMI correlates with poorer GBM prognosis. • Statistical model underscores age, MGMT status, and surgery type as key to GBM outcomes. • Study refutes obesity survival benefit, advocating for nuanced body composition metrics in GBM. Glioblastoma (GBM) is the most common primary brain cancer in adults with a very poor prognosis. Metabolic drivers of tumorigenesis are highly relevant within the central nervous system, where glucose is the critical source of energy. The impact of obesity on survival outcomes in patients with GBM is not well established. This study investigates the prognostic value of body mass index (BMI) in patients diagnosed with GBM. Adult patients with newly diagnosed GBM treated at Thomas Jefferson University Hospital between January 1, 2008, and December 31, 2022, were included in the study. BMI was calculated using the formula BMI = kg/m
2 . Patients BMI groups were underweight (BMI < 19.00), normal weight (BMI 19.00–24.99), overweight (BMI 25–29.99), and obese (BMI > 30.00). All patients received 60 Gy of radiation therapy with concurrent and adjuvant temozolomide following maximal safe resection. A difference in clinical outcomes of overall survival (OS) and progression-free survival (PFS) were evaluated between the groups using Kaplan-Meier and log-rank tests. A total of 392 patients met inclusion criteria. The median age was 60.3 (range 18.9–86.7), with 144 females and 248 males. Median BMI was 27.0 (Range; 17.7–52.9). Non-overweight GBM patients (BMI < 25.00, OS 2.1 years, CI 1.7–2.4 years) had increased overall survival compared to overweight patients (BMI ≥ 25.00, OS 1.5 years, CI 1.4–1.6 years) (p < 0.001). Patients with MGMT-methylated GBM also had significantly greater OS and PFS compared to MGMT-unmethylated patients (p < 0.001). Non-overweight GBM patients (BMI < 25.00, median PFS 1.5 years, CI 1.3–2.0 years) also had increased progression-free survival compared to overweight patients (BMI ≥ 25.00, median PFS 1.1 years, CI 0.9–1.2 years) (p < 0.001). Our study indicates normal BMI (19.00–24.99) at the time of GBM diagnosis is a favorable prognostic indicator for overall and progression-free survival. Additional studies are warranted for further analysis of BMI and survival outcomes in GBM patients. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
4. Fibre supplementation
- Author
-
Simone, Charles B, Simone, Nicole L, Bonithon-Kopp, Claire, and Faivre, Jean
- Subjects
Fiber in human nutrition -- Physiological aspects ,High-fiber diet -- Health aspects ,Intestinal polyps -- Prevention ,Colorectal cancer -- Care and treatment - Published
- 2001
5. Markers and associations of nutrition identified in a senior adult oncology clinic.
- Author
-
Lombardo, Joseph, Schmucker, Abigail M., Keith, Scott W., Ronghe, Ashwini, Smith, Alexandria, Ali, Ayesha S., Niazi, Muneeb, Denton, Melissa, Swartz, Kristine, Chapman, Andrew, and Simone, Nicole L.
- Published
- 2023
- Full Text
- View/download PDF
6. A single activity with a practice quality improvement project for faculty and a quality improvement project for residents.
- Author
-
Kim, Hyun, Malatesta, Theresa M., Simone, Nicole L., Den, Robert B., McAna, John, Dicker, Adam P., and Bar Ad, Voichita
- Abstract
Purpose The Next Accreditation System (NAS) requires radiation oncology residents to do a formal quality improvement project during their residency. The American Board of Radiology (ABR) Maintenance of Certification (MOC) program requires certified physicians to complete a Practice Quality Improvement (PQI) project approximately every 3 years. The purpose of our project was to develop a clinical transition of care policy via a process that resulted in quality improvement project credit for residents and PQI credit for participating faculty. Methods and materials Approval for project implementation was obtained from the ABR MOC committee. The PQI project consisted of an initial survey to assess resident perception on resident transition of care in our department, formal sign-out training, and 2 postintervention surveys after 1 and 11 months. The primary endpoint was the percentage of questions with ≤ 1 unfavorable responses. Sign-test was used to determine response difference from neutral. Results One hundred percent of surveyed residents completed the preintervention (n = 6), postintervention 1 (n = 7), and postintervention 2 (n = 8) surveys. In the preintervention, postintervention 1, and postintervention 2 surveys, 71.4%, 57.1%, and 57.1% of questions were answered with ≤ 1 unfavorable response, respectively. The number of questions with ≥ 75% favorable response was 7 (50%), 7 (50%), and 11 (78.5%) in the preintervention, postintervention 1, and postintervention 2 surveys, respectively ( P = .13). A written sign-out template and monthly protected sign-out meetings were instituted. One resident and 3 attending physicians received credit for Accreditation Council of Graduate Medical Education NAS quality improvement and ABR MOC PQI projects, respectively. Conclusions This project shows the feasibility of a combined attending and resident physician effort to improve patient care and fulfill his or her respective ABR MOC PQI and Accreditation Council of Graduate Medical Education NAS requirements. Attending and resident physicians can tailor collaborative projects to fulfill MOC and NAS requirements unique to their subspecialty. Written sign-out templates and protected sign-out time may improve transition of care. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold.
- Author
-
Eldredge-Hindy, Harriet B., Duffy, Danielle, Yamoah, Kosj, Simone, Nicole L., Skowronski, Jenna, Dicker, Adam P., and Anne, Pramila R.
- Abstract
Purpose Deep inspiration breath hold (DIBH) dramatically reduces radiation dose to the heart during radiation therapy (RT) for left-sided breast cancer, but the subsequent risk of radiation-related ischemic heart disease (IHD) is unknown. Our primary objective was to quantify the risk of IHD following RT with DIBH using modeled risk estimates (MRE). Methods and materials Patients with stage 0-III left-sided breast cancer who received RT with DIBH were retrospectively studied. Computed tomography simulations were performed with DIBH and during free breathing (FB) for comparison of dosimetry. Patients were classified as high risk, at risk, or at optimal risk for IHD and baseline risk estimates for IHD were obtained from historic controls. The excess relative risk of IHD because of left breast RT was calculated using patient-specific dosimetry and an existing dose-effect model. MRE were determined from the sum of baseline risk estimates and excess risk. Results Between 2002 and 2011, 111 patients were treated using DIBH and 104 were available for analysis. MRE for 10-year risk of IHD with DIBH and FB were 3.25% (interquartile range [IQR], 1.20-3.44) and 3.64% (IQR, 1.43-3.81) ( P < .0001), respectively. MRE for lifetime risk of IHD with DIBH and FB were 9.71% (IQR, 1.98-16.62) and 10.28% (IQR, 2.05-16.97) ( P < .0001), respectively. MRE were significantly reduced by use of DIBH in all risk groups. The largest absolute risk reduction resulting from the DIBH technique was observed in patients at high risk for IHD. The median relative risk reduction in MRE resulting from DIBH was 11.4% (range, 0-32.0) and 6.4% (range, 0-23.4) at 10 years and throughout the patients’ lifetime, respectively. After a median follow-up of 7.0 years (range, 1.3-11.2), the estimated 10-year freedom from IHD was 99.0% (95% confidence interval 93.4-99.8). Conclusions RT with DIBH may provide breast cancer survivors a clinically significant reduction in the risk of IHD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Active Breathing Coordinator reduces radiation dose to the heart and preserves local control in patients with left breast cancer: Report of a prospective trial.
- Author
-
Eldredge-Hindy, Harriet, Lockamy, Virginia, Crawford, Albert, Nettleton, Virginia, Werner-Wasik, Maria, Siglin, Joshua, Simone, Nicole L., Sidhu, Kulbir, and Anne, Pramila R.
- Abstract
Purpose Incidental radiation dose to the heart and lung during breast radiation therapy (RT) has been associated with an increased risk of cardiopulmonary morbidity. We conducted a prospective trial to determine if RT with the Active Breathing Coordinator (ABC) can reduce the mean heart dose (MHD) by ≥ 20% and dose to the lung. Methods and materials Patients with stages 0-III left breast cancer (LBC) were enrolled and underwent simulation with both free breathing (FB) and ABC for comparison of dosimetry. ABC was used during the patient’s RT course if the MHD was reduced by ≥ 5%. The median prescription dose was 50.4 Gy plus a boost in 77 patients (90%). The primary endpoint was the magnitude of MHD reduction when comparing ABC to FB. Secondary endpoints included dose reduction to the heart and lung, procedural success rate, and adverse events. Results A total of 112 patients with LBC were enrolled from 2002 to 2011 and 86 eligible patients underwent both FB and ABC simulation. Ultimately, 81 patients received RT using ABC, corresponding to 72% procedural success. The primary endpoint was achieved as use of ABC reduced MHD by 20% or greater in 88% of patients ( P < .0001). The median values for absolute and relative reduction in MHD were 1.7 Gy and 62%, respectively. RT with ABC provided a statistically significant dose reduction to the left lung. After a median follow up of 81 months, 8-year estimates of locoregional relapse, disease-free, and overall survival were 7%, 90%, and 96%, respectively. Conclusions ABC was well tolerated and significantly reduced MHD while preserving local control. Use of the ABC device during RT should be considered to reduce the risk of ischemic heart disease in populations at risk. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Intrarectal Amifostine During External Beam Radiation Therapy for Prostate Cancer Produces Significant Improvements in Quality of Life Measured by EPIC Score
- Author
-
Simone, Nicole L., Ménard, Cynthia, Soule, Benjamin P., Albert, Paul S., Guion, Peter, Smith, Sharon, Godette, Denise, Crouse, Nancy S., Sciuto, Linda C., Cooley-Zgela, Theresa, Camphausen, Kevin, Coleman, C. Norman, and Singh, Anurag K.
- Subjects
- *
PROSTATE cancer , *MALE reproductive organs , *CANCER patients , *THERAPEUTICS - Abstract
Purpose: To test whether intrarectal amifostine limits symptoms of radiation proctitis, measured by using the Radiation Therapy Oncology Group (RTOG) gastrointestinal (GI) toxicity score and the Expanded Prostate Cancer Index Composite (EPIC) score. Methods and Materials: Patients with localized prostate cancer received amifostine as a rectal suspension 30–45 minutes before daily three-dimensional conformal radiation therapy. The first 18 patients received 1 g of amifostine, and the next 12 patients received 2 g. Toxicity was assessed at baseline, during treatment, and at follow-up visits by using RTOG grading and the EPIC Quality of Life (QoL) 50-item questionnaire. The Bowel Function subset of the bowel domain (EPIC-BF), which targets symptom severity, and the Bowel Bother subset of the bowel domain (EPIC-BB), which assesses QoL, were evaluated and compared with the RTOG GI toxicity score. Results: Median follow-up was 30 months (range, 18–36 months). Overall, EPIC-BF and EPIC-BB scores both tracked closely with the RTOG GI toxicity score. Seven weeks after the start of radiation therapy, the incidence of RTOG Grade 2 toxicity was 33% in the 1-g group (6/18 patients) compared with 0% (0/12 patients) in the 2-g group and trended toward statistical significance (p = 0.06). A significant difference between amifostine groups was observed using the EPIC-BF score at 7 weeks (p = 0.04). A difference in EPIC-BB scores between dose groups was evident at 7 weeks (p = 0.07) and was significant at 12 months (p = 0.04). Conclusions: Higher doses of amifostine produced significant improvements in acute and late bowel QoL (up to 1 year after therapy), measured using the EPIC score. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
10. A comparative study using time-driven activity-based costing in single-fraction breast high-dose rate brachytherapy: An integrated brachytherapy suite vs. decentralized workflow.
- Author
-
Squeo, Gabriella C., Lattimore, Courtney M., Simone, Nicole L., Suralik, Greg, Dutta, Sunil W., Schad, Michael D., Su, Lucy, Libby, Bruce, Janowski, Einsley-Marie, Showalter, Shayna L., Lobo, Jennifer M., and Showalter, Timothy N.
- Subjects
- *
INTRAOPERATIVE radiotherapy , *ACTIVITY-based costing , *RADIOISOTOPE brachytherapy , *LABOR costs , *PRODUCT costing , *BREAST surgery - Abstract
Precision breast intraoperative radiation therapy (PB -IORT) is a novel approach to adjuvant radiation therapy for early-stage breast cancer performed as part of a phase II clinical trial at two institutions. One institution performs the entire procedure in an integrated brachytherapy suite which contains a CT-on-rails imaging unit and full anesthesia capabilities. At the other, breast conserving surgery and radiation therapy take place in two separate locations. Here, we utilize time-driven activity-based costing (TDABC) to compare these two models for the delivery of PB-IORT. Process maps were created to describe each step required to deliver PB -IORT at each institution, including personnel, equipment, and supplies. Time investment was estimated for each step. The capacity cost rate was determined for each resource, and total costs of care were then calculated by multiplying the capacity cost rates by the time estimate for the process step and adding any additional product costs. PB -IORT costs less to deliver at a distributed facility, as is more commonly available, than an integrated brachytherapy suite ($3,262.22 vs. $3,996.01). The largest source of costs in both settings ($2,400) was consumable supplies, including the brachytherapy balloon applicator. The difference in costs for the two facility types was driven by personnel costs ($1,263.41 vs. $764.89). In the integrated facility, increased time required by radiation oncology nursing and the anesthesia attending translated to the greatest increases in cost. Equipment costs were also slightly higher in the integrated suite setting ($332.60 vs. $97.33). The overall cost of care is higher when utilizing an integrated brachytherapy suite to deliver PB- IORT. This was primarily driven by additional personnel costs from nursing and anesthesia, although the greatest cost of delivery in both settings was the disposable brachytherapy applicator. These differences in cost must be balanced against the potential impact on patient experience with these approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Prospective Trial of Functional Lung Avoidance Radiation Therapy for Lung Cancer: Quality of Life Report.
- Author
-
Lombardo, Joseph, Castillo, Edward, Castillo, Richard, Miller, Ryan, Jones, Bernard, Miften, Moyed, Kavanagh, Brian, Dicker, Adam, Boyle, Cullen, Leiby, Benjamin, Banks, Joshua, Simone, Nicole L., Movsas, Benjamin, Grills, Inga, Guerrero, Thomas, Rusthoven, Chad G., and Vinogradskiy, Yevgeniy
- Subjects
- *
CANCER patients , *NON-small-cell lung carcinoma , *CANCER radiotherapy , *END of treatment , *COMPUTED tomography - Abstract
A novel form of lung function imaging has been developed that uses 4-dimensional computed tomography (4DCT) data to generate lung ventilation images (4DCT-ventilation). Functional avoidance uses 4DCT-ventilation to reduce doses to functional lung with the aim of reducing pulmonary side effects. A phase 2, multicenter 4DCT-ventilation functional avoidance clinical trial was completed. The purpose of this work was to quantify changes in patient-reported outcomes (PROs) for patients treated with functional avoidance and determine which metrics are predictive of PRO changes. Patients with locally advanced lung cancer receiving curative-intent radiation therapy were accrued. Each patient had a 4DCT-ventilation image generated using 4DCT data and image processing. PRO instruments included the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire administered pretreatment; at the end of treatment; and at 3, 6, and 12 months posttreatment. Using the FACT-Trial Outcome Index and the FACT-Lung Cancer Subscale results, the percentage of clinically meaningful declines (CMDs) were determined. A linear mixed-effects model was used to determine which patient, clinical, dose, and dose-function metrics were predictive of PRO decline. Of the 59 patients who completed baseline PRO surveys. 83% had non-small cell lung cancer, with 75% having stage 3 disease. The median dose was 60 Gy in 30 fractions. CMD FACT-Trial Outcome Index decline was 46.3%, 38.5%, and 26.8%, at 3, 6, and 12 months, respectively. CMD FACT-Lung Cancer Subscale decline was 33.3%, 33.3%, and 29.3%, at 3, 6, and 12 months, respectively. Although an increase in most dose and dose-function parameters was associated with a modest decline in PROs, none of the results were significant (all P >.053). The current work presents an innovative combination of use of functional avoidance and PRO assessment and is the first report of PROs for patients treated with prospective 4DCT-ventilation functional avoidance. Approximately 30% of patients had clinically significant decline in PROs at 12 months posttreatment. The study provides additional data on outcomes with 4DCT-ventilation functional avoidance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.
- Author
-
Manukian, Gregor, Kivolowitz, Charles, DeAngelis, Tiziana, Shastri, Anuradha A., Savage, Jason E., Camphausen, Kevin, Rodeck, Ulrich, Zarif, Jelani C., Simone, Nicole L., Shastri, Anuradha, and Zarif, Jelani
- Subjects
- *
REGULATORY T cells , *T cells , *LOW-calorie diet , *TRIPLE-negative breast cancer , *TUMOR microenvironment , *FLOW cytometry , *PROTEINS , *DISEASE progression , *RESEARCH , *ANIMAL experimentation , *INTERLEUKIN-2 , *GROWTH factors , *RESEARCH methodology , *CELL physiology , *CELL receptors , *IMMUNOSUPPRESSION , *MEDICAL cooperation , *EVALUATION research , *LYMPHOCYTES , *DIET therapy , *COMPARATIVE studies , *STATISTICAL sampling , *COMBINED modality therapy , *BREAST tumors , *MICE , *ANTIGENS , *PHYSIOLOGICAL effects of radiation , *BLOOD - Abstract
Outcomes for triple negative breast cancer (TNBC) are poor and may be improved by increasing CD8+ tumor infiltrating lymphocytes (TIL) to augment antitumor immunity. Radiation (RT) can promote immunogenic cell death with increased antitumor T cell activity but also stimulates suppressive regulatory T cells (Tregs). Because metabolic alterations affect immune homeostasis and prior studies show caloric restriction (CR) combined with RT improves preclinical TNBC outcomes, we hypothesized that CR augments RT, in part, by altering intratumoral immunity. Using an in vivo model of TNBC, we treated mice with ad libitum (AL) diet, radiation, a CR diet, or CR + RT, and demonstrated an immune suppressive environment with a significant increase in CD4+ CD25+Foxp3+ Tregs after RT but not in CR-fed mice. CD8:Treg ratio in CR + RT TIL increased 4-fold compared with AL + RT mice. In vivo CD8 depletion was performed to assess the role of effector T cells in mitigating the effects of CR, and it was found that in mice undergoing CR, depletion of CD8 T cells resulted in increased tumor progression and decreased median survival compared with isotype control-treated mice. In addition, PD-1 expression on CD3+CD8+ T cells within the tumor microenvironment was significantly increased in CR + RT versus AL + RT treated mice as per immunofluorescence. Serum from breast cancer patients undergoing RT alone or CR and RT was collected pre- and postintervention, and a cytokine array demonstrated that patients treated with CR + RT had notable decreases in immunosuppressive cytokines such as IL-2Rγ, IL-10Rβ, and TGF-β2 and 3 compared with patients receiving RT alone. In conclusion, combining CR with RT decreases intratumoral Tregs, increases CD8:Treg, and increases PD-1 expression via a process dependent on CD8 T cells in a TNBC model. Breast cancer patients undergoing CR concurrently with RT also had significant reduction in immunosuppressive cytokine levels compared with those receiving RT alone. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Exercise Therapy and Radiation Therapy for Cancer: A Systematic Review.
- Author
-
Zaorsky, Nicholas G., Allenby, Taylor, Lin, John, Rosenberg, Jennifer, Simone, Nicole L., and Schmitz, Kathryn H.
- Subjects
- *
EXERCISE therapy , *HEAD & neck cancer , *AEROBIC capacity , *PHYSICAL mobility , *BREAST cancer , *CANCER radiotherapy , *RADIOTHERAPY , *TUMOR treatment , *SYSTEMATIC reviews , *TUMORS - Abstract
Purpose: Exercise therapy (ET) is shown to improve toxicity and surrogates of survival for patients receiving chemotherapy. Current National Comprehensive Cancer Network (NCCN) guidelines lack recommendations for concurrent radiation therapy (RT) and ET. The main objective was to determine the impact of concurrent ET + RT with respect to (1) acceptability, feasibility, safety; and (2) to demonstrate how incorporating ET in cancer treatment can enhance patient-reported outcomes (PROs) and physical function-defined as strength or exercise capacity.Methods and Materials: A PICOS/PRISMA selection protocol was used to search PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), and Cochrane Review for prospective randomized controlled trials evaluating concurrent ET + RT, including >10 patients and with 1 or more study arms. Acceptability, feasibility, and safety rates were calculated. PROs were assessed with study-specific metrics. Physical function was defined as improvements in strength or range of motion. Statistically significant improvement was defined by P <.05.Results: Twenty-six of 693 screened studies including 1563 patients (831 receiving exercise, 732 controls) with localized breast cancer (67.1% of patients), prostate cancer (27.4%), head and neck cancers (2.8%), and spinal metastases (2.8%) were assessed. Objective 1: Among 3385 patients approached for ET, 1864 (55.1%) accepted the treatment; of those, 1563 patients (83.9%) completed the trials. Objective 2: Statistical improvements were noted in these PROs: quality of life (14 of 15 studies), fatigue (12 of 16 studies), mood/depression (9 of 13), and anxiety (6 of 7). Physical function improved statically in 16 of 16 studies.Conclusions: Combination ET + RT is safe and well-tolerated with improvements in PROs and physical function. Additional studies are needed in patients with metastatic cancers to assess survival and to compare effectiveness of different exercise regimens. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. Toxicity and cosmetic outcomes after treatment with a novel form of breast IORT.
- Author
-
Meneveau, Max O., Petroni, Gina R., Varhegyi, Nikole E., Hulse, John C., Schroen, Anneke T., Brenin, David R., Janowski, Einsley M., Berger, Adam C., Lazar, Melissa A., Simone, Nicole L., Showalter, Timothy N., and Showalter, Shayna L.
- Subjects
- *
ACCELERATED partial breast irradiation , *INTRAOPERATIVE radiotherapy , *BREAST , *TREATMENT effectiveness - Abstract
Intraoperative radiation therapy (IORT), a form of accelerated partial breast irradiation (APBI), is an appealing alternative to postoperative whole breast irradiation for early-stage breast cancer. The purpose of this study was to examine the toxicity and cosmetic outcomes of patients treated with a novel form of breast IORT (precision breast IORT; PB -IORT), that delivers a targeted, higher dose of radiation than conventional IORT. The first 204 patients treated with PB -IORT in a Phase II clinical trial (NCT02400658) with 12 months of followup were included. Trial inclusion criteria were age ≥45 years, invasive or in situ breast cancer, tumor size ≤3 cm, and node negative. Toxicity and cosmetic scoring were performed at 6 and 12 months. 98 patients (48%; 95% CI, 41–55%) experienced toxicity. Seven Grade 3 toxicities occurred (3.4%; 95% CI, 1.4–6.9%). Most patients (95%) had excellent or good cosmetic outcomes (95% CI, 91–98%) at 12 months. Most patients (94%) had little or no pigmentation change (95% CI, 90–97%), 88% little to no size change (95% CI, 82–92%), and 87% experienced minimal shape change (95% CI, 82–92%). Overall, Grade 3+ toxicity was rare and cosmetic outcomes were excellent. Severe toxicity with PB -IORT is similar to that reported in the TARGIT trial (3.3% rate of major toxicity) but lower than APBI (NSABP-39, 10.1% Grade 3/4 toxicities). We propose that the toxicity of PB -IORT compared with TARGIT and NSABP-39 is related to the radiation dose and delivery schedule. PB -IORT offers low-toxicity and good cosmetic outcomes when compared with other forms of APBI. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. MicroRNA-21 is Required for Hematopoietic Cell Viability After Radiation Exposure.
- Author
-
Puccetti, Matthew V, Adams, Clare M, Dan, Tu D, Palagani, Ajay, Simone, Brittany A, DeAngelis, Tiziana, Eischen, Christine M, and Simone, Nicole L
- Abstract
Purpose: Radiation therapy is an essential intervention used in the treatment of more than half of cancer patients. With the increasing use of hypofractionated radiation regimens, concurrent use of radiation and chemotherapy, targeted agents and immunotherapy, the risk of radiation-induced toxicities is increased. However, much remains unknown about the molecular underpinnings responsible for radiation-induced toxicity. MicroRNA (miRNA) are small, non-coding RNA involved in post-transcriptional regulation of gene expression. miR-21 is an oncomiR that is dysregulated in a significant fraction of human malignancies, and its overexpression is linked to poor overall survival, chemoresistance, and radioresistance in several human cancers. However, the contribution of miR-21 in governing radiation sensitivity in normal, untransformed cells, and the impact of silencing this miRNA in normal tissues remains largely unexplored.Materials and Methods: miR-21 levels were evaluated in tissues by qRT-PCR without and after total body irradiation (TBI). Mice lacking miR-21 were genetically engineered, subjected to TBI, and monitored for survival. Hematopoietic stem and progenitor cell (HSPC) numbers and function were assessed using flow cytometry, histology, complete blood cell counts, and bone marrow transplantation.Results: miR-21 expression was increased in radiosensitive tissues, but not in radioinsensitive tissues following TBI in wild-type mice, suggesting it may have a critical function in the normal tissue response to irradiation. Compared to wild-type mice, mice lacking one or both alleles of miR-21 showed reduced numbers of HSPCs and increased sensitivity to an LD50/30 dose of TBI with evidence of bone marrow failure. Transplantation of wild-type bone marrow into irradiated miR-21-deficient mice rescued the mice from death.Conclusions: Our data identify miR-21 as a critical component of HSPC viability and essential for bone marrow recovery following irradiation. Further investigation is warranted to determine whether miR-21 can be used to stratify patients at risk for hematopoietic toxicity following irradiation. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence.
- Author
-
Arthur, Douglas W., Winter, Kathryn A., Kuerer, Henry M., Haffty, Bruce G., Cuttino, Laurie W., Todor, Dorin A., Simone, Nicole L., Hayes, Shelly B., Woodward, Wendy A., McCormick, Beryl, Cohen, Randi J., Sahijdak, Walter M., Canaday, Daniel J., Brown, Doris R., Currey, Adam D., Fisher, Christine M., Jagsi, Reshma, and White, Julia
- Subjects
- *
RADIOTHERAPY , *BREAST diseases , *BREAST surgery , *LUMPECTOMY , *DUCTAL carcinoma , *THERAPEUTICS , *ADENOCARCINOMA , *HUMAN body , *BREAST , *BREAST tumors , *CANCER relapse , *CLINICAL trials , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *ONCOLOGY , *RADIATION injuries , *REOPERATION , *RESEARCH , *RESEARCH funding , *SKIN , *EVALUATION research , *FIBROSIS - Abstract
Purpose: To determine the associated toxicity, tolerance, and safety of partial-breast reirradiation.Methods and Materials: Eligibility criteria included in-breast recurrence occurring >1 year after whole-breast irradiation, <3 cm, unifocal, and resected with negative margins. Partial-breast reirradiation was targeted to the surgical cavity plus 1.5 cm; a prescription dose of 45 Gy in 1.5 Gy twice daily for 30 treatments was used. The primary objective was to evaluate the rate of grade ≥3 treatment-related skin, fibrosis, and/or breast pain adverse events (AEs), occurring ≤1 year from re-treatment completion. A rate of ≥13% for these AEs in a cohort of 55 patients was determined to be unacceptable (86% power, 1-sided α = 0.07).Results: Between 2010 and 2013, 65 patients were accrued, and the first 55 eligible and with 1 year follow-up were analyzed. Median age was 68 years. Twenty-two patients had ductal carcinoma in situ, and 33 had invasive disease: 19 ≤1 cm, 13 >1 to ≤2 cm, and 1 >2 cm. All patients were clinically node negative. Systemic therapy was delivered in 51%. All treatment plans underwent quality review for contouring accuracy and dosimetric compliance. All treatment plans scored acceptable for tumor volume contouring and tumor volume dose-volume analysis. Only 4 (7%) scored unacceptable for organs at risk contouring and organs at risk dose-volume analysis. Treatment-related skin, fibrosis, and/or breast pain AEs were recorded as grade 1 in 64% and grade 2 in 7%, with only 1 (<2%) grade ≥3 and identified as grade 3 fibrosis of deep connective tissue.Conclusion: Partial-breast reirradiation with 3-dimensional conformal radiation therapy after second lumpectomy for patients experiencing in-breast failures after whole-breast irradiation is safe and feasible, with acceptable treatment quality achieved. Skin, fibrosis, and breast pain toxicity was acceptable, and grade 3 toxicity was rare. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. microRNA Alterations Driving Acute and Late Stages of Radiation-Induced Fibrosis in a Murine Skin Model.
- Author
-
Simone, Brittany A., Ly, David, Savage, Jason E., Hewitt, Stephen M., Dan, Tu D., Ylaya, Kris, Shankavaram, Uma, Meng Lim, Lianjin Jin, Camphausen, Kevin, Mitchell, James B., and Simone, Nicole L.
- Subjects
- *
MICRORNA , *FIBROSIS , *EFFECT of radiation on skin , *LABORATORY mice , *QUALITY of life , *TISSUE analysis , *CANCER radiotherapy complications - Abstract
Purpose Although ionizing radiation is critical in treating cancer, radiation-induced fibrosis (RIF) can have a devastating impact on patients' quality of life. The molecular changes leading to radiation-induced fibrosis must be elucidated so that novel treatments can be designed. Methods and Materials To determine whether microRNAs (miRs) could be responsible for RIF, the fibrotic process was induced in the right hind legs of 9-week old CH3 mice by a single-fraction dose of irradiation to 35 Gy, and the left leg served as an unirradiated control. Fibrosis was quantified by measurements of leg length compared with control leg length. By 120 days after irradiation, the irradiated legs were 20% (P=.013) shorter on average than were the control legs. Results Tissue analysis was done on muscle, skin, and subcutaneous tissue from irradiated and control legs. Fibrosis was noted on both gross and histologic examination by use of a pentachrome stain. Microarrays were performed at various times after irradiation, including 7 days, 14 days, 50 days, 90 days, and 120 days after irradiation. miR-15a, miR-21, miR-30a, and miR-34a were the miRs with the most significant alteration by array with miR-34a, proving most significant on confirmation by reverse transcriptase polymerase chain reaction, c-Met, a known effector of fibrosis and downstream molecule of miR-34a, was evaluated by use of 2 cell lines: HCT116 and 1522. The cell lines were exposed to various stressors to induce miR changes, specifically ionizing radiation. Additionally, in vitro transfections with pre-miRs and anti-miRs confirmed the relationship of miR-34a and c-Met. Conclusions Our data demonstrate an inverse relationship with miR-34a and c-Met; the upregulation of miR-34a in RIF causes inhibition of c-Met production. miRs may play a role in RIF; in particular, miR-34a should be investigated as a potential target to prevent or treat this devastating side effect of irradiation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
18. MicroRNA expression altered by diet: Can food be medicinal?
- Author
-
Palmer, Joshua D., Soule, Benjamin P., Simone, Brittany A., Zaorsky, Nicholas G., Jin, Lianjin, and Simone, Nicole L.
- Subjects
- *
MICRORNA genetics , *GENE expression , *DIET , *NON-coding RNA , *DISEASE progression , *HEALTH outcome assessment - Abstract
As the link between metabolism and major disease processes becomes more well-defined, the identification of key molecular targets is leading to new therapeutic strategies. As a result, small non-coding RNA molecules that regulate gene expression via epigenetic alterations, microRNAs have been identified as regulators of these metabolic processes. In the last decade, dietary interventions have been used to change metabolism and to potentially alter disease progression and clinical outcomes. These interventions have been linked, at a molecular level, to microRNAs. This review will summarize the role of various dietary strategies on the expression of several microRNA families. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
19. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer
- Author
-
Simone, Charles B., Ly, David, Dan, Tu D., Ondos, John, Ning, Holly, Belard, Arnaud, O’Connell, John, Miller, Robert W., and Simone, Nicole L.
- Subjects
- *
HEAD & neck cancer treatment , *CANCER radiotherapy , *RADIATION dosimetry , *PHYSIOLOGICAL effects of protons , *CANCER tomography , *COMPARATIVE studies - Abstract
Abstract: Background and purpose: Various radiotherapy planning methods for locally advanced squamous cell carcinoma of the head and neck (SCCHN) have been proposed to decrease normal tissue toxicity. We compare IMRT, adaptive IMRT, proton therapy (IMPT), and adaptive IMPT for SCCHN. Materials and methods: Initial and re-simulation CT images from 10 consecutive patients with SCCHN were used to quantify dosimetric differences between photon and proton therapy. Contouring was performed on both CTs, and plans (n =40 plans) and dose–volume histograms were generated. Results: The mean GTV volume decreased 53.4% with re-simulation. All plans provided comparable PTV coverage. Compared with IMRT, adaptive IMRT significantly reduced the maximum dose to the mandible (p =0.020) and mean doses to the contralateral parotid gland (p =0.049) and larynx (p =0.049). Compared with IMRT and adaptive IMRT, IMPT significantly lowered the maximum doses to the spinal cord (p <0.002 for both) and brainstem (p <0.002 for both) and mean doses to the larynx (p <0.002 for both) and ipsilateral (p =0.004 IMRT, p =0.050 adaptive) and contralateral (p <0.002 IMRT, p =0.010 adaptive) parotid glands. Adaptive IMPT significantly reduced doses to all critical structures compared with IMRT and adaptive IMRT and several critical structures compared with non-adaptive IMPT. Conclusions: Although adaptive IMRT reduced dose to several normal structures compared with standard IMRT, non-adaptive proton therapy had a more favorable dosimetric profile than IMRT or adaptive IMRT and may obviate the need for adaptive planning. Protons allowed significant sparing of the spinal cord, parotid glands, larynx, and brainstem and should be considered for SCCHN to decrease normal tissue toxicity while still providing optimal tumor coverage. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
20. The chemistry and biology of nitroxide compounds
- Author
-
Soule, Benjamin P., Hyodo, Fuminori, Matsumoto, Ken-ichiro, Simone, Nicole L., Cook, John A., Krishna, Murali C., and Mitchell, James B.
- Subjects
- *
NITROGEN oxides , *BLOOD circulation disorders , *MAGNETIC resonance imaging , *FREE radical reactions - Abstract
Abstract: Cyclic nitroxides are a diverse group of stable free radicals that have unique antioxidant properties. Because of their ability to interact with free radicals, they have been used for many years as biophysical tools. During the past 15–20 years, however, many interesting biochemical interactions have been discovered and harnessed for therapeutic applications. Biologically relevant effects of nitroxides have been described, including their ability to degrade superoxide and peroxide, inhibit Fenton reactions, and undergo radical–radical recombination. Cellular studies defined the activity of nitroxides in vitro. By modifying oxidative stress and altering the redox status of tissues, nitroxides have been found to interact with and alter many metabolic processes. These interactions can be exploited for therapeutic and research use, including protection against ionizing radiation, as probes in functional magnetic resonance imaging, cancer prevention and treatment, control of hypertension and weight, and protection from damage resulting from ischemia/reperfusion injury. Although much remains to be done, many applications have been well studied and some are currently being tested in clinical trials. The therapeutic and research uses of nitroxide compounds are reviewed here with a focus on the progress from initial development to modern trials. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
21. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study
- Author
-
Singh, Anurag K., Ménard, Cynthia, Guion, Peter, Simone, Nicole L., Smith, Sharon, Crouse, Nancy Sears, Godette, Denise J., Cooley-Zgela, Theresa, Sciuto, Linda C., Coleman, Jonathan, Pinto, Peter, Albert, Paul S., Camphausen, Kevin, and Coleman, C. Norman
- Subjects
- *
CANCER education , *MALE reproductive organs , *RADIOTHERAPY , *ONCOLOGY - Abstract
Purpose: Our goal was to test the ability of intrarectal amifostine to limit symptoms of radiation proctitis. Methods and Materials: The first 18 patients received 1 g of intrarectal amifostine suspension placed 30–45 min before each radiation treatment. The following 12 patients received 2 g of amifostine. Total dose prescribed ranged from 66 to 76 Gy. All patients were treated with three-dimensional conformal radiation therapy. The suspension remained intrarectal during treatment and was expelled after treatment. For gastrointestinal symptoms, during treatment and follow-up, all patients had a Radiation Therapy Oncology Group (RTOG) grade recorded. Results: Median follow-up was 18 months (range, 6–24 months). With 2 g vs. 1 g amifostine, there was a nearly significant decrease in RTOG Grade 2 acute rectal toxicity. Seven weeks after the start of radiation therapy, the incidence of Grade 2 toxicity was 33% in the 1-g group (6/18) compared with 0% (0/12) in the 2-g group (p = 0.06). No Grade 3 toxicity or greater occurred in this study. Conclusion: This trial suggests greater rectal radioprotection from acute effects with 2 g vs. 1 g amifostine suspension. Further studies should be conducted in populations at higher risk for developing symptomatic acute and late proctitis. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.